Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)

Type: Poster Session

Time: Saturday June 1, 8:00 AM to 11:00 AM

Location: Hall A

Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.

Sub-category:
New Targets and New Technologies (non-IO)

Category:
Developmental Therapeutics and Tumor Biology (Nonimmuno)

Meeting:
2019 ASCO Annual Meeting

Abstract No:
3102

Poster Board Number:
Poster Session (Board #94)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 3102)

Author(s): Marcelo Vailati Negrao, Victoria M. Raymond, Richard B. Lanman, Patrick Kwok Shing Ng, Rebecca Nagy, Kimberly Banks, Viola Weijia Zhu, Bianca E Amador, Emily Roarty, Young Kwang Chae, Jeffrey Melson Clarke, Jeffrey Crawford, Sai-Hong Ignatius Ou, David R. Gandara, John Heymach, Trever Grant Bivona, Caroline Elizabeth McCoach; Department of Thoracic / Head and Neck Medical Oncology - The University of Texas MD Anderson Cancer Center, Houston, TX; Guardant Health, Inc., Redwood City, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Duke University Medical Center, Durham, NC; Chao Family Comprehensive Cancer Center, University of California, Orange, CA; University of California, Davis, Sacramento, CA; University of California San Francisco, San Francisco, CA

Abstract Disclosures

Abstract:

Background: BRAF alterations (alts) account for ~4% of non-small cell lung cancers (NSCLC) with 50% being non-V600 alts. Because these alts are functionally heterogeneous and have a poorly characterized genomic landscape, determining appropriate treatment strategies is a challenge. Methods: The Guardant360 clinical database was queried for NSCLC patients (pts) with BRAF alts. Alts were categorized by clonality, type and class (1 and 2: BRAF monomer and dimer signaling; 3: requires co-occurring upstream RAS-mediated signaling). Functionality and drug screen assays were performed in Ba/F3 cells. Pts with non-V600 mutations were analyzed for sensitivity to MEK +/- BRAF inhibitors (M+Bi). Results: 306 unique BRAF alts were identified and the majority were observed once (233/306; 76%). Amplifications (806/1663; 48.5%) and missense alts (795/1663; 47.8%) were the most common occurrences. Missense alts were predominantly clonal (58%), and of known functionality (428/795; 54%). All class 1-2 alts were activating in Ba/F3 cells, while class 3 alts were found to have variable functionality (activating: 4/9). Functionality was correlated with clonality as demonstrated by class 1-3 alts having higher clonality compared to variants of unknown significance (VUS) (1: 56%; 2: 54%; 3: 45%; VUS: 38%; P<0.01). Drug screens for G469V and L597R alts showed resistance to first generation BRAF inhibitors (IC50 ≥100nM), but sensitivity to M+Bi (IC50 0.02-36nM). Growth inhibition was more pronounced for dabrafenib + trametinib (D+T) (IC50 <0.1nM) compared to encorafenib + binimetinib (IC50 8-35nM) and vemurafenib + cobimetinib (IC50 2-36nM). BRAF D594G mutation (class 3) was not activating in Ba/F3 cells. Three pts with non-V600 alts were treated with M+Bi. G469V and D594G had rapid disease progression (PFS 2 and 4 mos respectively), while pt with L597R has ongoing partial response (PFS 8+ mos). Conclusions:BRAF alts show correlation between clonality and functionality, which provides important clinical information given the numerous VUS in the BRAF non-V600 setting. Drug screens reveal non-V600 alts may be sensitive to M+Bi and suggest D+T is the most active combination. Clinical data supports that some non-V600 BRAF mutations may be sensitive to M+Bi.

 
Other Abstracts in this Sub-Category:

 

1. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3003 First Author: Marwan Fakih
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - New Targets and New Technologies (non-IO)

 

2. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3007 First Author: Johann S. De Bono
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - New Targets and New Technologies (non-IO)

 

3. A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3009 First Author: Mihaela C. Cristea
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - New Targets and New Technologies (non-IO)

 

More...